<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03460925</url>
  </required_header>
  <id_info>
    <org_study_id>IRENE-1</org_study_id>
    <nct_id>NCT03460925</nct_id>
  </id_info>
  <brief_title>Improving REsectability in Pancreatic NEoplasms (IRENE)</brief_title>
  <acronym>IRENE</acronym>
  <official_title>Interventional Multicentric Study Without Medicine, in Patients Affected by Locally Advanced Pancreatic Adenocarcinoma: Stereotactic Radiotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of clinical response in terms of resectability of patients with locally advanced
      pancreatic cancer treated with neoadjuvant chemotherapy plus stereotactic body radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the study is to define the percentage of patients with down-staging and clinical
      response after having undergone stereotactic radiotherapy + chemotherapy with neoadjuvant
      intent for locally advanced pancreatic carcinoma or &quot;borderline resectable&quot; at the time of
      diagnosis.

      The study evaluates the response to therapy in terms of resectability, of acute and delayed
      treatment-related toxicity, of overall survival and progression-free survival and also
      assesses patient's quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response to the treatment in terms of resectability</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of patients with pancreatic cancer judged to be inoperable who have undergone surgical treatment after neoadjuvant chemotherapy plus stereotactic body radiotherapy. Response is evaluated with CT-scan and 18F FDG PET-scan (RECIST criteria) by a multidisciplinary team of surgeons, radiologist, oncologist, radiation oncologist according to resectability criteria NCCN v. 2017.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Months of survival since the diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Progression-free survival (PFS) after radiotherapy is evaluated with CT-scan and 18F FDG PET-scan (RECIST criteria). Also laboratory tests are performed (CA 19.9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>24 months</time_frame>
    <description>Acute and late toxicities after radiotherapy are assessed with CTCAE v. 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>24 months</time_frame>
    <description>QoL are assessed with CLAS (contentment with life assessment scale)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Stereotactic Body Radiotherapy</condition>
  <arm_group>
    <arm_group_label>SBRT plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with unresectable or &quot;borderline resectable&quot; locally advanced pancreatic carcinoma at time of diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT plus chemotherapy</intervention_name>
    <description>Neoadjuvant stereotactic body radiotherapy (SBRT, 30 Gy in 5 fractions) plus chemotherapy with Folfirinox</description>
    <arm_group_label>SBRT plus chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological diagnosis of locally advanced pancreatic carcinoma, not upfront
             surgically treated (according to NCCN resectability criteria), without distant
             metastases

          -  NCCN criteria resectability status

          -  patient's age, performance status, possible presence of comorbidity should also be
             considered to decide the optimal approach (upfront surgery versus neoadjuvant
             treatment).

          -  If the chemotherapy treatment induces the disease to a condition of resectability, the
             patient will undergo a surgical evaluation

          -  indication for radiotherapy treatment

          -  ECOG 0-2

          -  obtaining informed consent

          -  not pregnant or breastfeeding

        Exclusion Criteria:

          -  ECOG&gt; 2

          -  presence of internal diseases for which radiotherapy is contraindicated, or diseases
             of the connective system, or gastric or duodenal ulcer in progress or acute
             diverticulitis, ulcerative colitis

          -  comorbidity which in the opinion of the referring physician may constitute a risk for
             participation in the study

          -  lack of availability for clinical-instrumental follow-up

          -  previous abdominal radiotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessio G Morganti, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessio G Morganti, MD</last_name>
    <phone>+390512143564</phone>
    <email>rt.unibo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S.Orsola-Malpighi Hospital</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessio G Morganti, MD</last_name>
      <phone>+390512143564</phone>
      <email>rt.unibo@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>G</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>Alessio Giuseppe Morganti</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>stereotactic body radiotherapy</keyword>
  <keyword>resectability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

